This page shows the latest Cancer therapy news and features for those working in and with pharma, biotech and healthcare.
The trial results showed a drop of 32% in cancer recurrence when using Verzenios in combination with endocrine therapy. ... The trial showed that adjuvant treatment using Verzenios in combination with endocrine therapy decreased the risk of breast cancer
Lung cancer is the cancer with the highest mortality rate and accounts for more than one in five (21%) of all deaths caused by cancer. ... There are treatment options available for those diagnosed with stage 3 NSCLC, however if a patient progresses to
The site, situated in the US, is set to produce Kite’s FDA-approved CAR T-cell therapy used to treat blood cancers. ... CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment.
positive unresectable locally advanced or metastatic breast cancer after two, or more prior anti-HER2 treatments. ... Dr Alicia Okines, consultant medical oncologist at The Royal Marsden NHS Foundation Trust and team leader for the Breast Cancer Systemic
Nearly 80% of these patients received Lumakras as a third-line or later therapy. ... Although there have been advances in treatment, few improvements have been made to significantly improve the diagnosis and treatment of pancreatic cancer.
Diabetes medicine Trulicity (dulaglutide), immunology blockbuster Taltz (ixekizumab), breast cancer therapy Verzenio (abemaciclib) and migraine prevention antibody Emgality (galcanezumab-gnlm) each saw revenues rise by more than 30% year on year.
More from news
Approximately 1 fully matching, plus 490 partially matching documents found.
Selumetinib was given ‘breakthrough therapy’ status and rapidly green-lit by the FDA last month (April) following a promising National Cancer Institute (NCI) Cancer Therapy Evaluation Program sponsored phase 2 trial. ... targets of small cell lung
There was no robust, regulatory control but that has changed and any cell therapy now has to be properly approved.”. ... Tightening up regulatory policies was vital in order to move on from the cell therapy lowlight that saw a 21-year-old student die
and Braftovi) that Pfizer thinks could become a top industry franchise in colorectal cancer when combined with antibody drug cetuximab. ... to 2025 built on the Prevnar franchise, rare disease therapy Vyndaqel (tafamidis), breast cancer therapy Ibrance
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer
Diefenbach said: “The promise of being able to tailor cancer therapy to biology and risk is at the forefront of the drive to discover novel biomarkers. ... The idea of cancer biomarkers is to find one that exists to the exclusion or near-exclusion of
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell
transplantation. He joins from ZMKS International Cancer Therapy Biotechnologies, a Chinese immuno-oncology company, where he served as chief scientific officer and director of research and development.
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.
protect us from infectious diseases – to recognise and kill cancer cells. ... Atir achieved some extremely compelling clinical data and the phase II study interim analysis in December demonstrated the drug's true potential as an adjunctive life-saving
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
iii] Lobo R.A. Hormone-replacement therapy: Current thinking. Nat. Rev. Endocrinol. 2017; 13:220–231. ... iv] Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study.
Ovarian cancer – novel therapeutic approaches. Cancer Therapy Advisor 2017. Available at: https://www.cancertherapyadvisor.com/obstetrics-and-gynecology/ovarian-cancer-novel-therapeutic-approaches/article/617855/. ... Accessed April 2019. 8. Target
This year’s theme focused on securing access to optimal cancer care – a poignant topic and one that resonates across the healthcare sector, impacting patients in all walks of life. ... Ipsen Group developed an eye-catching attraction to offset this
of genes along with less known cancer therapy recommendations. ... to recommend genetic testing to high-risk breast cancer patients, despite the women asking for tests.
In 2017 Blue Latitude Health was asked to develop differentiated and convincing global messaging for physicians helping prostate cancer patients. ... The therapy was well-established in the more advanced disease stage, but it was still a novelty when
More from PMHub
Approximately 0 fully matching, plus 10 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...